Mandate

Vinge has advised Stenhus Fastigheter i Norden AB in connection with their uplisting to Nasdaq Stockholm

Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.

Stenhus Fastigheter is a real estate company that owns and manages public properties and commercial properties with a clear geographic focus on urban areas and growth cities. Stenhus Fastigheter also works actively with existing and potential building rights within the current portfolio.

Vinge’s team consisted mainly of Rikard Lindahl, Joel Magnusson and Michaela Ådén (Capital Markets and Public M&A), Diana Kanold (VDR), Victor Ericsson, Emelie Svanberg, Marcus Svärd and Ellenor Eckerborn (Tax), Nicklas Thorgerzon and Siri Blomberg (IT och GDPR), Ebba Svenburg and Jonna Skog (Employment), Kristoffer Larson, Madelene Andersson and Sara Franson (Real Estate), Lina Österberg (Environment), Ida Redander, August Ahlin and William Carlberg Johansson (Banking and Finance) and Hayaat Ibrahim and Jonna Fransson (Compliance).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026